The iconic rise of copyright’s flagship product presented a massive prospect for shareholders , but its period has expired , creating a complex landscape. Off-brand versions have appeared in the arena, diminishing sales and putting pressure on profit percentages . While major pharmaceutical companies hold a presence in this sector , the outlook s